{
  "docId": "019de076-2351-76a2-9dc5-1c75bf1dd158",
  "docSlug": "905d9ceaf5cb608feb86b583a8401e54",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 45,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 30,
  "notes": "The slide uses a dual-column layout to contrast a strategic roadmap for Tagrisso with a competitive performance chart for Calquence.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-2351-76a2-9dc5-1c75bf1dd158/16",
  "deckHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158",
  "deckJsonHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158.json",
  "deckAnchorHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.225
      },
      "kind": "chart",
      "text": "Calquence maintaining BTKi leadership in face of competition",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ea38bcdb-7440-4047-898f-2623e4b8fac6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.03,
        "y": 0.225
      },
      "kind": "diagram",
      "text": "Establishing Tagrisso for every EGFRm patient",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "27dc5c75-064c-42dd-912f-3f8642248c28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.52,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "Sustained 1L CLL leadership, recovery in r/r share",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "069815be-c956-40ae-815b-9a97b3bc8290",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "LCM and combination opportunities reinforce Tagrisso as backbone TKI",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "39b4ab3e-d28a-489d-9f8b-8bdedc9ec284",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.915
      },
      "kind": "source-note",
      "text": "Source: Based on internal new to brand prescription (NBRx) analysis by AstraZeneca UK Limited using IQVIA US National Prescription Audit Market Dynamics (NPA MD) for the period of September 2023.",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32aede97-02c0-4848-be5c-8520801a83e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Leading value propositions, commercial execution reinforce future growth opportunity",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f67625e6-697f-44e6-8bcb-577d8dd311c9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology – Tagrisso and Calquence",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "180c8a6f-d225-444c-ab4c-0f6091d74c5a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "2e49daf6-b09f-497d-be7c-d40751175288",
      "evidence": "The use of a line chart and a paragraph discussing leadership in CLL implies a 2x2 matrix.",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "action-titles",
      "slug": null,
      "matchId": "b29cd05c-db9b-43a4-a3ef-4d65f66873db",
      "evidence": "The slide uses a clear, thesis-driven headline summarizing the strategic takeaway.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "88166dd9-a0d1-4ffb-ac51-e141aedff5d2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Key takeaways and highlights from Oncology and BioPharmaceuticals",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "4272c71f-edd6-48f7-a353-789a42575177",
      "evidence": "The document walks through a logical chain of financial performance, portfolio evolution, and R&D highlights",
      "position": 0,
      "objective": "How AstraZeneca's diversified portfolio drives growth",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    },
    {
      "to": 20,
      "from": 13,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f01e337f-a074-4bb0-a0a6-8afab8af6ed6",
      "evidence": "The document highlights the potential consequences of inaction in not leveraging technology for better patient outcomes",
      "position": 1,
      "objective": "The importance of harnessing technology to deliver better patient outcomes",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}